Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.

@article{Wu2003SurgicalTO,
  title={Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.},
  author={Peter C. Wu and Alex Langerman and Christopher W. Ryan and John P Hart and Susan Swiger and Mitchell C. Posner},
  journal={Surgery},
  year={2003},
  volume={134 4},
  pages={656-65; discussion 665-6}
}
BACKGROUND Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors that are characterized by constitutive overexpression of the tyrosine kinase receptor KIT (CD117). Imatinib mesylate is a selective inhibitor of tyrosine kinase-mediated activity. This study reports a single-institution experience of surgical resection and the use of imatinib in the treatment of GIST. METHODS A retrospective review from 1995 to 2002 identified 57 patients (M:F, 29:28; median age, 61 years) with GIST… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…